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Abstract
The discovery that thymic epithelium from many species expresses a large repertoire of genes encoding neuroendocrine and other tissue-
restricted antigens has radically changed our knowledge of the pathogenic mechanisms underlying the development of organ-specific
autoimmune diseases such as type 1 diabetes and autoimmune endocrine diseases. Rather than a breakdown of immunological self-
tolerance in periphery, there is mounting evidence that the diabetogenic autoimmune response may first arise from a thymus dysfunction
in the central programming of β-cell self-tolerance. Insulin-like growth factor 2 (IGF-2) is the dominant member of the insulin gene/protein
family expressed in thymic epithelial cells (TECs) from different species, and Igf2-/- mice fail to programme complete tolerance to insulin.
Based on the homology between insulin, the primary and immunogenic auto-antigen of type 1 diabetes, and IGF-2, the tolerogenic self-
antigen of the insulin family, the design of a regulatory/negative self-vaccination for prevention against type 1 diabetes has been proposed
and is under development.
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In distant species and invertebrates, the foundations of the
neuroendocrine and immune systems have co-existed until now
without any apparent problem. Some 470 millions years ago, while
gene conversion already determined some rudiments of immune
diversity in primitive vertebrates (such as jawless fishes), adaptive
immunity emerged in lymphoid cells of cartilaginous fishes (i.e. sharks
and rays). Adaptive immune response is characterised by enzymatic
machinery specialising in the random recombination of gene
segments encoding the variable parts of B-cell receptor (BCR) and 
T-cell receptor (TCR) for antigens. The emergence of this sophisticated
defence system exerted a very potent pressure for the appearance 
of lymphoid structures and pathways necessary to impose
immunological self-tolerance, i.e. the inability of the immune system to
react against the host organism. The first thymus appeared in
cartilaginous fishes concomitantly or very shortly after adaptive
immunity. This organ is not an endocrine gland, but it stands at the
crucial intersection between the immune and neuroendocrine
systems.1 Among all lymphoid tissues, the thymus is unique in that it is
the only place where there is a permanent confrontation between
ancient, almost constant, neuroendocrine principles and a more
recently evolved system equipped with machinery that stochastically
generates diversity of the adaptive immune response. The progressive
rise in the level of immune diversity and complexity may explain why
failures in self-tolerance (systemic and organ-specific autoimmune
diseases) are increasingly detected during evolution, with most such
failures observed in the human species. Because the intrathymic
education is so complex, mistakes easily occur, leading to thymic
output of self-reactive T lymphocytes orientated against components
of the neuroendocrine system and other peripheral tissues. Contrary
to the assumption that has prevailed for a very long time, the thymus
operates throughout life, and it plays a fundamental role in generating
the peripheral repertoire of T lymphocytes that are diverse, self-
tolerant and competent against non-self antigens.
Thymus Physiology and the 
Nature of ‘Neuroendocrine Self’
The thymus constitutes the central arm of immunological self-tolerance
by two essential mechanisms that are complementary and intimately
associated: clonal deletion of self-reactive T cells issued from the
random recombination of TCR genes (negative selection), and
generation of self-antigen-specific natural regulatory T cells (nTreg) that
are able to inactivate in peripheral self-reactive T cells having escaped
intrathymic negative selection.2
For a long time, it was thought that tissue-specific antigens targeted by
autoimmune responses were sequestered from T cells during their
differentiation in the thymus. However, we and several other groups
have demonstrated that thymic epithelial cells (TECs) from different
species constitute a site for promiscuous transcription of a great
number of genes belonging to neuroendocrine families, such as the
neurohypophysial family,3 tachykinins,4 neurotensins5 and the insulin
family.6,7 The nature of neuroendocrine self was then defined as follows:7
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• Neuroendocrine self-antigens usually correspond to peptide
sequences that have been the most conserved throughout the
evolution of a given family.
• Some hierarchy characterises their expression profile in the thymus.
For the neurohypophysial family, oxytocin (OT) is the dominant
peptide expressed in TECs from different species. OT binding to
neurohypophysial receptors expressed by thymic T cells promotes a
rapid phosphorylation of focal adhesion-related kinases,8 and this
event could play an important role in the induction of immune
synapses between TECs and developing pre-T cells. For the insulin
family, insulin-like growth factor 2 (IGF-2) is the dominant peptide
expressed by cortical and medullary TECs, while IGF-1 is detected in
thymic macrophages, and insulin in very rare subsets of medullary
TECs.9 Such a hierarchy is significant because the level of tolerance
to a protein is highly correlated to the level of its expression in the
thymus. High IGF-2 concentration in the thymus may explain why this
protein is highly tolerated, whereas intrinsic immunogenicity of
insulin may actually result due to its low expression in rare medullary
TEC subsets. Furthermore, in murine foetal thymic organ cultures, the
blockade of signalling between IGFs and their receptors (but not 
the blockade of proinsulin) severely interferes with intrathymic T-cell
proliferation and differentiation.10
• In the thymus, neuroendocrine precursors are not processed
according to the classic model of neurosecretion, but through
pathways of antigen presentation by, or in association with, proteins
of the major histocompatibility complex (MHC).5
This hierarchy in the organisation of the thymic repertoire of
neuroendocrine self-antigens is also significant from an evolutionary
point of view. As discussed above, some physiological and essential
functions emerged before the development of adaptive immunity had
to be protected from its inherent risk of autotoxicity. Therefore, OT as
a peptide, implicated at different steps of reproductive biology and
thus in species preservation, had to be protected to a greater degree
than vasopressin (VP), which essentially controls water metabolism.
Also, IGF-2 as a major growth factor in foetal development had to be
protected to a greater extent than insulin, which is responsible for
glucose homeostasis. Nevertheless, because of their homology,
neuroendocrine self-antigens expressed in the thymus may promote
cross-tolerance to other members of their respective families. This was
recently demonstrated by the weaker tolerance to insulin of Igf2-/-
mice compared with wild-type mice.11 Further insight into the
discrimination between the respective power of central and peripheral
arms of immunological self-tolerance will be gained through the
generation of mice with TEC-specific Igf2 deletion that is under current
development in our laboratory. 
Failure in Thymus Programming of Central 
Self-tolerance as an Initial Event in the
Development of Type 1 Diabetes and
Autoimmune Endocrinopathies (see Figure 1)
We have previously postulated that a defect in T-cell education to
recognise and tolerate OT in the thymus could play a crucial role in the
development of an autoimmune response selective of hypothalamic
magnocellular neurones leading to an ‘idiopathic’ central diabetes
insipidus.12 As formulated by Burnet in 1973, the essential pathogenesis
of autoimmune diseases may first depend on the appearance of
‘forbidden’ self-reactive T cells in the peripheral T-cell repertoire.13 Since
the thymus is the first site implicated in the establishment of
immunological self-tolerance, thorough investigation of the mechanisms
responsible for a failure of thymic censorship will provide the scientific
community with novel important keys for understanding the
development of autoimmune processes. This was the essential objective
of the FP6 Integrated Project Euro-Thymaide (www.eurothymaide.org)
co-ordinated by the University of Liège. Abnormalities of the morphology
and cytoarchitecture of the thymus have been described in several
autoimmune diseases. Apoptosis of self-reactive T cells is also defective
in the thymus of the NOD mouse, an animal model of human type 1
diabetes.14 Transcription of insulin-related genes (Ins, Igf1 and Igf2) has
been analysed in the thymus of both diabetes-prone (BB-DP) and
diabetes-resistant (BB-DR) rats, another animal model of type 1 diabetes.
Ins and Igf1 transcripts were detected in all thymi from BB-DP and BB-
DR rats. Igf2 transcripts were also present in the thymus from all BB-DR
rats, but were absent in the thymus from more than 80% of BB-DP rats,
in close concordance with the incidence of autoimmune diabetes in
those rats (86%).15 This defect of Igf2 transcription in the thymus of 
BB-DP rats may contribute to both their lymphopenia (including absence
of nTreg) and to the absence of central self-tolerance to insulin-secreting
islet cells. Other authors have shown that susceptibility to autoimmune
diabetes is correlated with the level of Ins2 transcription in the mouse
thymus.16,17 Compared with the human foetus, with long alleles (class III)
of variable number of tandem repeats (VNTR) located upstream of the
INS and IGF2 loci, INS transcripts are lower in the thymus of human
foetus carrying short alleles (class II) of VNTR, an important genetic trait
determining susceptibility to type 1 diabetes (IDDM2).18,19
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Figure 1: Thymus-dependent Programming of 
Central T-cell Self-tolerance and Role of Thymus
Dysfunction in the Development of Type 1 Diabetes 
and Autoimmune Endocrine Diseases
Thymus Physiology
Transcription by thymic epithelium of a series of
neuroendocrine-related genes
Deletion of T cells expressing a TCR with high affinity
for neuroendocrine self-antigens
Generation of natural Treg Foxp3+, specific for
neuroendocrine self-antigens
Control by AIRE of the intrathymic transcription of
neuroendocrine self-antigens
Thymus Pathophysiology
Absence of or decrease in thymic
expression/presentation of neuroendocrine self-
antigens (APECED/APS-I syndrome, Aire-/- mouse, NOD
mouse, BB rat, etc.)
Enrichment of T-cell peripheral pool with
neuroendocrine self-reactive T cells
Decrease in neuroendocrine self-specific natural 
Treg generation
Molecular Bridge Between Self-reactive T cells and 
Endocrine Targets
Influence of genetic elements intra- and extra-MHC
Influence of environmental factors (virus, diet, stress)
During whole life, the thymus generates effector T cells (Teff) that are competent against
non-self antigens and self-tolerant, as well as self-specific natural regulatory T cells (Treg).
Thymic epithelium is the site of expression for many genes encoding neuroendocrine self-
antigens and tissue-restricted antigens. The AIRE gene controls transcription of most of
those genes. Self-antigen expression in the thymus intervenes both in negative selection of
self-reactive T cells and in positive selection of self-antigen specific natural Treg. Absence of
or decrease in thymic self-antigen expression as observed in several animal models of
autoimmunity will lead to the enrichment of the peripheral pool with self-reactive T cells,
while generation of self-antigen-specific natural Treg will be significantly decreased. Both
genetic and environmental factors seem to be involved in the establishment of a molecular
‘bridge’ between self-reactive T cells and the endocrine antigenic targets. Once this bridge is
formed, the autoimmune pathogenic process can be triggered and progressively leads to
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The demonstration that TECs are also the site for transcription of genes
encoding thyroid antigens (thyroglobulin, thyroperoxydase and thyroid-
secreting hormone [TSH] receptor) strongly suggests that central self-
tolerance to thyrocytes also concerns these proteins specific to thyroid
metabolism.20,21 Thymic hyperplasia has been described in patients with
Graves’ disease (type 3 autoimmune disease). This thymic hyperplasia
regresses after treatment, and is not found in other cases of
thyrotoxicosis from other origins (such as toxic thyroid adenoma).22
The identification of the autoImmune regulator gene (AIRE) resulted in
further demonstration that thymus dysfunction plays a crucial role in
the pathogenesis of organ-specific autoimmune diseases.23 AIRE single
mutations are responsible for a rare autosomal recessive disorder
named autoimmune polyendocrine syndrome type 1 (APS-I) or
autoimmune polyendocrinopathy, candidiasis and ectodermal
dystrophy (APECED, Online Mendelian Inheritance in Man [OMIM]
240300). This syndrome develops in early childhood and is
characterised by multiorgan autoimmunity and hypofunction of several
endocrine organs such as the parathyroid glands, adrenal cortex and
sexual gonads. AIRE codes for a 54kD protein sharing structural
characteristics with transcription factors, and AIRE expression is
maximal in the thymus, mainly in medullary TECs. Depending on their
genetic background, Aire-/- mice exhibit several signs of peripheral
autoimmunity, which are associated with a very significant decrease in
thymus transcription of neuroendocrine and tissue-specific genes
(including Ot, Npy, Igf2 and Ins2).24 A recent study has also shown that
both AIRE and VNTR class II alleles (IDDM2) determine the level of INS
transcription in the human thymus.25
Although hypoparathyroidism is a hallmark of APS-1, a candidate
parathyroid autoantigen has only recently been identified as the NACHT
leucine-rich-repeat protein 5 (NALP5),26 which is selectively expressed in
the cytoplasm of parathyroid cells. Interestingly, the NALP protein/gene
family includes 14 members, and only NALP6 and NALP9 transcripts have
been identified in the human thymus, suggesting that they could be
responsible for inducing central self-tolerance to the whole family.
The presence of a balance between predisposing and protective loci
that determines individual genetic susceptibility is not sufficient to
trigger autoimmune diseases. In addition to these genetic components,
environmental factors (such as viral infections, nutrition, lifestyle and
even stressful events) are implicated in the pathogenesis of these
disorders. With regard to type 1 diabetes, we have shown that infection
of human and murine thymus with the diabetogenic coxsackievirus B4
(CVB4) results in a severe thymus dysfunction that could enhance CVB4
virulence through induction of tolerance to CVB4 and play a role in the
breakdown of central self-tolerance to islet β cells.27,28 Nevertheless,
genetic factors are also implicated in the modulation of environmental
triggers for autoimmune diseases, and very recently IFIH1, a gene
implicated in interferon response to viral RNA infections, was shown to
protect against type 1 diabetes.29
Conclusions and Perspectives
During last few years, many studies have clearly demonstrated the
crucial role played by the thymus in programming central self-tolerance.
More and more experimental arguments argue for a defect in thymic
(central) tolerogenic function as an initial event in the development of
organ-specific autoimmune diseases such as type 1 diabetes and other
autoimmune endocrinopathies. According to their processing either as
cognate ligands for neuroendocrine receptors expressed by immature 
T cells or as self-antigens presented by thymic MHC proteins, thymic
neuroendocrine precursors exert a dual role that transposes at the
molecular level the dual role played by the thymus in T-cell development
and negative selection. There exists a close homology, but not an
absolute identity, between these neuroendocrine self-antigens and the
peripheral targets of autoimmune responses. VP is the autoantigen
targeted in some cases of ‘idiopathic’ central diabetes insipidus,30–32
while tolerance to OT is so strong that cases of autoimmune response
against OT have never been described. Analogously, insulin is the
primary immunogenic autoantigen in type 1 diabetes,33,34 while tolerance
to IGF-2 is very difficult to break. According to Burnet, immunological
tolerance to an antigen when established during foetal life is supposed
to be ‘unbreakable’. If future studies confirm that the high level of
tolerance to a thymic self-antigen is correlated with the active
tolerogenic properties of this self-antigen in periphery, a novel type of
vaccination could be developed. Contrary to classic vaccination, which
is the source of immunogenic response and immune memory,
negative/regulatory ‘self-vaccination’ could help in reprogramming
immunological self-tolerance, which is absent in autoimmune diseases
from foetal life and development.35 n 
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